The Endocannabinoid System: Working With What We Already Have
To understand how cannabis affects the brain, you first need to understand that cannabis doesn't introduce something foreign into your neurology, it hijacks something already there.
The endocannabinoid system (ECS) is one of the most widespread neurotransmitter systems in the human body. It runs through the brain, the nervous system, and virtually every major organ, regulating an extraordinary range of functions: mood, memory, sleep, appetite, pain perception, immune response, and stress regulation. Your body produces its own cannabinoids naturally, anandamide and 2-AG are the primary ones, which bind to CB1 and CB2 receptors throughout the body to keep these systems in balance.
This is a finely calibrated system. It is not designed to receive the levels of cannabinoid stimulation that come from regular cannabis use, and certainly not from the high-potency THC products that now dominate the market. When THC, the primary psychoactive compound in cannabis, floods CB1 receptors in the brain, it doesn't simply replicate what your natural endocannabinoids do. It overwhelms the system, and over time, the brain responds by downregulating its own receptors, producing less of its own cannabinoids, and becoming increasingly dependent on external input to maintain baseline function.
This is not a metaphor. This is measurable, documented neurological change, and it is the biological foundation of cannabis dependence and withdrawal.
Dependence: More Common Than People Think
Cannabis use disorder is real, clinically recognised, and significantly underestimated in public discourse. According to the National Institute on Drug Abuse, approximately 9% of people who use cannabis will develop dependence, a figure that rises to around 17% among those who begin in adolescence, and to nearly 50% among daily users.
Globally, cannabis is the third most commonly used psychoactive substance after alcohol and tobacco, with the United Nations Office on Drugs and Crime estimating around 209 million users worldwide. As use increases and potency rises, so does the prevalence of cannabis use disorder. A 2022 analysis published in The Lancet Psychiatry found that rates of cannabis use disorder have increased substantially in countries where high-potency products have become widely available.
These are not fringe users or people with unusual vulnerability. They are ordinary people who began using cannabis socially, found it increasingly difficult to stop, and discovered too late that "harmless" had never been quite the right word.
Anxiety: The Uncomfortable Paradox
One of the most common reasons people reach for cannabis is anxiety relief. The irony is that cannabis is simultaneously one of the most anxiety-provoking substances a person can use.
In the short term, many users do experience relaxation and reduced anxiety, particularly at lower doses and in familiar settings. But the relationship between cannabis and anxiety is dose-dependent, highly individual, and far less straightforward than the wellness industry would have us believe. At higher doses, THC reliably produces anxiety, paranoia, and in some cases acute panic, effects well documented in controlled studies. A 2017 review in Psychopharmacology confirmed that THC produces dose-dependent increases in anxiety and paranoia in healthy volunteers, with higher-potency products producing more pronounced effects.
Anxiety Rebound: The Trap Inside the Relief
When someone uses cannabis regularly to manage anxiety, their endocannabinoid system adapts. CB1 receptors downregulate, natural anandamide production decreases, and the brain's baseline capacity to regulate stress and anxiety diminishes. The person now needs cannabis not to feel good, but simply to feel normal, and when they don't have it, their anxiety returns with a force that often exceeds what they experienced before they began using.
This is anxiety rebound, and it is one of the most commonly reported features of cannabis withdrawal. Studies show that anxiety, irritability, and sleep disruption are among the most prominent and persistent withdrawal symptoms, typically peaking within the first week of cessation and lasting several weeks in regular users. A 2020 study in Drug and Alcohol Dependence found that anxiety symptoms during cannabis withdrawal were significant enough to drive relapse in a substantial proportion of participants, people who resumed use not for pleasure but simply to escape the anxiety that stopping had caused.
The tragedy here is clear:
A person begins using cannabis to manage anxiety. The cannabis use itself erodes their brain's natural anxiety regulation. They now experience more anxiety without cannabis than they ever did before they started. They use more cannabis to manage the anxiety their cannabis use created. The cycle tightens, and what began as relief becomes a trap.
Cannabis and Psychosis: A Relationship the Evidence Can No Longer Ignore
The link between cannabis use and psychosis is one of the most robustly evidenced and most frequently dismissed findings in modern psychiatry. The dismissal is understandable, it is an uncomfortable truth that disrupts a tidy narrative about a popular substance, but the evidence has reached a point where dismissal is no longer scientifically defensible.
Multiple large-scale longitudinal studies across different countries and populations have found consistent associations between cannabis use and psychotic disorders. The relationship is:
- Dose-dependent, heavier use is associated with greater risk
- Potency-dependent, high-THC products carry substantially more risk
- Age-dependent, adolescent use carries significantly higher risk than adult initiation
A landmark 2019 study published in The Lancet Psychiatry examined data across eleven sites in Europe and Brazil and found that:
- Daily cannabis use was associated with a threefold increase in the odds of a psychotic disorder
- Daily use of high-potency cannabis was associated with a fivefold increase
- If high-potency cannabis were no longer available, approximately 12% of cases of psychosis in the study sample could have been prevented
These are not small numbers. These are not statistical artefacts. This is a significant, preventable public health burden.
Why the Endocannabinoid System Is Central to This Risk
CB1 receptors are particularly dense in regions of the brain centrally involved in psychosis: the prefrontal cortex, the hippocampus, the striatum, and the anterior cingulate cortex. These are the areas that regulate thought organisation, reality testing, emotional processing, and the filtering of sensory information.
When THC floods these receptors, particularly at high doses or with prolonged exposure, it disrupts the delicate signalling balance that keeps these functions operating normally. It increases dopamine release in the striatum, a mechanism directly implicated in the positive symptoms of psychosis such as hallucinations and delusions. It impairs glutamate signalling in ways that mirror the neurotransmitter dysfunction seen in schizophrenia. And in individuals who carry genetic vulnerabilities, variants in genes like COMT and AKT1, this disruption can tip the brain across the threshold into a psychotic episode that may not resolve when the drug does.
Cannabis does not cause psychosis in everyone who uses it. But it meaningfully increases the probability of psychosis in people who are vulnerable, and vulnerability is rarely visible in advance.
The Potency Problem
Any honest conversation about cannabis risk must grapple with a simple fact: the cannabis available today is not the cannabis of twenty or thirty years ago.
Average THC concentrations in cannabis products have risen dramatically over recent decades. Concentrated products like wax, shatter, and oils can reach THC concentrations of 70–90%, compared to the 4–8% typical of cannabis in the 1990s.
This matters enormously, because the risks described above, anxiety, dependence, withdrawal, psychosis, are all dose and potency dependent. The research establishing cannabis as "relatively harmless" was largely conducted on populations using substantially weaker products. Applying those conclusions to today's high-potency market is not just outdated, it is scientifically unjustifiable.
A 2021 review in Psychological Medicine found that exposure to high-potency cannabis was associated with:
- A greater risk of psychosis
- More severe dependence
- Worse mental health outcomes overall
As markets have shifted toward higher potency, driven by consumer demand and commercial incentives, the risk landscape has shifted with them, and public understanding has not kept pace.
Adolescents: The Highest Stakes
The developing brain deserves specific mention, because the risks of cannabis are not evenly distributed across the lifespan. The adolescent brain is undergoing a critical period of development that continues well into the mid-twenties, and the endocannabinoid system is directly involved in orchestrating that development, guiding synaptic pruning, neural migration, and the maturation of the prefrontal cortex.
Introducing exogenous THC into this process is not neutral. Studies consistently find that adolescent-onset cannabis use is associated with:
- Worse cognitive outcomes
- Greater risk of dependence
- Higher rates of psychotic disorder
- Poorer educational and occupational attainment
A large longitudinal study following participants over 25 years found that persistent cannabis use beginning in adolescence was associated with measurable neuropsychological decline, declines that were not fully reversed by adult cessation.
Holding Nuance Without Losing Truth
None of this means cannabis has no legitimate medical applications. Cannabidiol (CBD), the non-psychoactive cannabinoid, has demonstrated genuine therapeutic value in specific contexts, most notably in treatment-resistant epilepsy. And there are populations and conditions where medically supervised cannabis use may offer real benefit.
But medical nuance should not be weaponised to dismiss recreational risk. The "it has medical uses, therefore it's harmless" logic would not survive contact with opioids, benzodiazepines, or stimulants, all of which have legitimate medical applications and significant harm potential. Cannabis deserves the same honest, evidence-based treatment we would give any other pharmacologically active substance.
The myth of harmlessness is not a small mistake. It shapes how people use, how much they use, how early they start, and whether they take seriously the signs that something is going wrong. Replacing it with accurate, nuanced information is not an anti-cannabis position.
It is a pro-people one, because people can only make genuinely free choices when they are working with the truth.